Hepatosteatosis prevalence in patients with type 2 diabetes mellitus

Conclusion: In our study, we concluded that hepatosteatosis is increased in patients with type II diabetes mellitus independent of other hepatosteatosis risk factors, in comparison to control group.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Purpose: The presence of hepatosteatosis in type 2 diabetics is a well-known but poorly investigated subject.

📊

Key Findings & Data:In our study, we investigated hepatosteatosis prevalence in type 2 diabetics using ultrasonography.

💡

Conclusion & Impact:Conclusion: In our study, we concluded that hepatosteatosis is increased in patients with type II diabetes mellitus independent of other hepatosteatosis risk factors, in comparison to control group.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Transaminazlar · Karaciğer hastalıkları · Lipidler

Abstract

Purpose: The presence of hepatosteatosis in type 2 diabetics is a well-known but poorly investigated subject. In our study, we investigated hepatosteatosis prevalence in type 2 diabetics using ultrasonography. Material and method: 50 diabetic and 50 non-diabetic patients who applying from various clinics were included in our study. None of the patients had. chronic alcohol abuse history.Body mass index (BMI), serum transaminase and lip id levels are also evaluated. All patients were evaluated by Diasonics synergy multisync m500 ultrasonography. Results: Hepatosteatosis was determined in 30 patients in diabetic group (% 60) and 12 patients in control group (% 24) by using ultrasonography (p < 0.01). There was no significant statistical difference between two groups in regard of body mass index (BMI), serum, transaminase and serum lipid levels (p>0.05). Conclusion: In our study, we concluded that hepatosteatosis is increased in patients with type II diabetes mellitus independent of other hepatosteatosis risk factors, in comparison to control group.

Özet

Amaç: Tip 2 diyabette hepatosteatoz varlığı, bilinen fakat yeterince incelenmemiş bir konudur. Çalışmamızda, transabdominal ultrasonografi kullanarak tip 2 diyabetli olgularda hepatosteatoz varlığını araştırdık. Gereç ve Yöntem: Çalışmamıza, çeşitli kliniklerden başvuran, 50 diyabetik ve 50 non- diyahetik hasta dahil edildi. Çalışmaya dahil edilen hastaların hiçbirinde kronik alkol kullanımı öyküsü yoktu. Çalışmada, hastaların beden-kitle indeksi (BKİ), transaminaz düzeyleri ve kan lipid profilleri göz önüne alındı. Tüm incelemeler Diasonics synergy multisync mSOO ultrasonografi cihazı ile yapıldı. Bulgular: Diabetik grupta 30 hastada (% 60), kontrol grubunda ise 12 hastada (% 24) USG ile hepatosteatoz belirlendi (p 0.05). Sonuç: Çalışmamızda, tip 2 DM 'lu hastalarda, hepatosteatoza neden olan diğer etkenlerden bağımsız olarak, kontrol grubu ile kıyaslandığında hepatosteatoz oranının arttığını saptadık.

Keywords

Transaminazlar Karaciğer hastalıkları Lipidler Yağlı karaciğer Diabetes mellitus tip 2 Vücut kitle indeksi Transaminases Liver Diseases Lipids Fatty Liver Diabetes Mellitus Type 2 Body Mass Index

🔖

Cite This Article

KAHRAMAN, A. D., HALEFOĞLU, A. M., YILMAZ, N., KAHRAMAN, A. N., TÜRK, B., MAHMUTOĞLU, A. S., BAŞAK, M. (2005). Hepatosteatosis prevalence in patients with type 2 diabetes mellitus. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 39 - Sayı: 2, 32–35. https://ajindex.com/articles/363532

References (1)

Lee RG, Keefle EB.Non - alcoholic fatty liver: causes and complications.In: J Bircher, JP Benhamou, M Mclntyre et al, eds. Oxford Textbook of Clinical Hepatology, 2nd ed. Oxford Textbook of Clinical Hepatology, 2nd ed. Oxford, UK: Oxford University Press; 1999:1251-1257 2. HYMAN G: Mechanisms of anemia in human cancer. Proc. Am. A Cancer Research 1(2):22, 1954. 3. BAUMAN MA, BRAND K, GIELD J, HERMANEK P, RUF S, SCHEELE J, HOFERICHTER S: Significance of serum phosphexose isomerase (PHI) in patients with gastrointestinal, kidney and breast cancer. Cancer. Invest. 8(3-4): 351-6, 1990. 4. BAUMANN M, KAPPL A, LANG T, BRAND K, SI- EGFRİEND W, PATEROK E: The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney and breast cancer. Cancer Invest. 8(3-4):351-6, 1990. 5. BODANSKY O: Serum phosphohexose isomerase in cancer. Cancer 7:1191 -1199, 1954. 6. BODANSKY O: Enzymes and cancer. In Proceedings of the First Conference on Cancer Diagnostic Tests (1950). Pub Health Service Publ. No. 96. Washington DC, 1951, s.43-53. 7. BOSSMAN HB, HALL TC: Enzyme activity in invasive tumors of humon breast and colon. Proc Natl Acad Sci USA. 71:1833-1837, 1974. 8. FILELLA X, MOLINA R, ESTAPE J, BALLESTA AM: Phosphohexose isomerase and carcinoembryonic antigen in the sera of patients with primary lung cancer. Int J Biol markers. Vol 3(2): 113-122, 1988. 9. HENNIPMAN A, VAN OIRSCHOT BA, SMITS J, RIJKSEN G, STAAL GE: Glicolytic enzyme activities ine breast cancer. Metastases. Tumor Biol 9(5):241-8, 1988. 10. JOPLIN GF, JEGATHEESON K: Serum glycolytic enzymes and acid phosphatases im mammary carcinomatosis. Br Med J 1:827, 1962. 11. ROSE A, WEST M, ZIMMERMAN HJ: Serum enzymes in disease. V. lsocitric dehydrogenase, malic dehydrogenase, and glycolytic enzymes in patients with carcinoma of the breast. Cancer 14:726, 196.1. 12. SANTABARBARA P, MOLINA P, ESTAPE J, BALLESTA AM: Phosphohexose isomerase and carcinoembryonic antigen in the sera of patients with primary lung cancer. In J Biol Markers Vol 3(2): 113-112, 1988. 13. SCHWARTZ MA, WEST M, WALSH W, ZIMMERMAN HJ: -Serum enzymes in disease. X. Glycolytic and oxidative enzymes and transaminases in patients with carcinoma of head, neck ad esophagus. Cancer 15:927,1962. 14. SHAPOT VS: Biochemical Aspects of Tumour Growth, Moscow: Mir Publ, 1980. 15. TRAN CO, COHEN J, WEST M, ZIMMERMAN HJ: Serum enzymes in diseases. XIV. Abnormality of levies of transaminases and glycolytic a